[1] |
KONG XY, GAO J. Macrophage polarization: A key event in the secondary phase of acute spinal cord injury[J]. J Cell Mol Med, 2017, 21(5): 941-954. doi: 10.1111/jcmm.13034
|
[2] |
DIMITRIJEVIC MR, DANNER SM, MAYR W. Neurocontrol of movement in humans with spinal cord injury[J]. Artif Organs, 2015, 39(10): 823-833. doi: 10.1111/aor.12614
|
[3] |
WANG HW, LIU XW, ZHAO YW, et al. Incidence and pattern of traumatic spinal fractures and associated spinal cord injury resulting from motor vehicle collisions in China over 11 years[J]. Medicine, 2016, 95(43): e5220. doi: 10.1097/MD.0000000000005220
|
[4] |
WANG YL, YUAN YT, GAO YT, et al. MicroRNA-31 regulating apoptosis by mediating the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in treatment of spinal cord injury[J]. Brain Dev, 2019, 41(8): 649-661. doi: 10.1016/j.braindev.2019.04.010
|
[5] |
YANG R, GUO L, HUANG L, et al. Epidemiological characteristics of traumatic spinal cord injury in Guangdong, China[J]. Spine, 2017, 42(9): E555-E561. doi: 10.1097/BRS.0000000000001896
|
[6] |
ALIZADEH A, DYCK SM, KARIMI-ABDOLREZAEE S. Traumatic spinal cord injury: An overview of pathophysiology, models and acute injury mechanisms[J]. Front Neurol, 2019, 10: 282. doi: 10.3389/fneur.2019.00282
|
[7] |
ZHENG YJ, REN WY, ZHANG LN, et al. A review of the pharmacological action of Astragalus polysaccharide[J]. Front Pharmacol, 2020, 11: 349. doi: 10.3389/fphar.2020.00349
|
[8] |
LUO YM, QIN Z, HONG Z, et al. Astragaloside Ⅳ protects against ischemic brain injury in a murine model of transient focal ischemia[J]. Neurosci Lett, 2004, 363(3): 218-223. doi: 10.1016/j.neulet.2004.03.036
|
[9] |
WEI RD, LIU HD, CHEN R, et al. Astragaloside Ⅳ combating liver cirrhosis through the PI3K/Akt/mTOR signaling pathway[J]. Exp Ther Med, 2019, 17(1): 393-397.
|
[10] |
ZHU JH, WEN K. Astragaloside Ⅳ inhibits TGF-β1-induced epithelial-mesenchymal transition through inhibition of the PI3K/Akt/NF-κB pathway in gastric cancer cells[J]. Phytother Res, 2018, 32(7): 1289-1296. doi: 10.1002/ptr.6057
|
[11] |
LU WS, LI S, GUO WW, et al. Effects of astragaloside Ⅳ on diabetic nephropathy in rats[J]. Genet Mol Res, 2015, 14(2): 5427-5434. doi: 10.4238/2015.May.22.12
|
[12] |
COSTA IM, LIMA FOV, FERNANDES LCB, et al. Astragaloside Ⅳ supplementation promotes a neuroprotective effect in experimental models of neurological disorders: A systematic review[J]. Curr Neuropharmacol, 2019, 17(7): 648-665. doi: 10.2174/1570159X16666180911123341
|
[13] |
LIU GY, SONG JM, GUO YL, et al. Astragalus injection protects cerebral ischemic injury by inhibiting neuronal apoptosis and the expression of JNK3 after cerebral ischemia reperfusion in rats[J]. Behav Brain Funct, 2013, 9: 36. doi: 10.1186/1744-9081-9-36
|
[14] |
ZHOU LY, SONG ZF, ZHOU LW, et al. Protective role of Astragalus injection in spinal cord ischemia-reperfusion injury in rats[J]. Neurosciences, 2018, 23(2): 116-121. doi: 10.17712/nsj.2018.4.20170391
|
[15] |
YUE RC, LI X, CHEN BY, et al. Astragaloside Ⅳ attenuates glutamate-induced neurotoxicity in PC12 cells through raf-MEK-ERK pathway[J]. PLoS ONE, 2015, 10(5): e0126603. doi: 10.1371/journal.pone.0126603
|
[16] |
YIN F, ZHOU HF, FANG YC, et al. Astragaloside Ⅳ alleviates ischemia reperfusion-induced apoptosis by inhibiting the activation of key factors in death receptor pathway and mitochondrial pathway[J]. J Ethnopharmacol, 2020, 248: 112319. doi: 10.1016/j.jep.2019.112319
|
[17] |
YAO NW, LU Y, SHI LQ, et al. Neuroprotective effect of combining tanshinone ⅡA with low-dose methylprednisolone following acute spinal cord injury in rats[J]. Exp Ther Med, 2017, 13(5): 2193-2202. doi: 10.3892/etm.2017.4271
|
[18] |
XU J, KIM GM, CHEN SW, et al. iNOS and nitrotyrosine expression after spinal cord injury[J]. J Neurotrauma, 2001, 18(5): 523-532. doi: 10.1089/089771501300227323
|
[19] |
SINGH C, ROY-CHOWDHURI S. Quantitative real-time PCR: Recent advances[J]. Methods Mol Biol, 2016, 1392: 161-176.
|
[20] |
KHORASANIZADEH M, YOUSEFIFARD M, ESKIAN M, et al. Neurological recovery following traumatic spinal cord injury: A systematic review and meta-analysis[J]. J Neurosurg Spine, 2019, 30(5): 683-699. doi: 10.3171/2018.10.SPINE18802
|
[21] |
WANG HL, ZHOU QH, XU MB, et al. Astragaloside Ⅳ for experimental focal cerebral ischemia: Preclinical evidence and possible mechanisms[J]. Oxidat Med Cell Longev, 2017, 2017: 8424326.
|
[22] |
XIA L, GUO DX, CHEN B. Neuroprotective effects of astragaloside Ⅳ on Parkinson disease models of mice and primary astrocytes[J]. Exp Ther Med, 2017, 14(6): 5569-5575.
|
[23] |
LIN JL, PAN XX, HUANG CHONGAN, et al. Dual regulation of microglia and neurons by Astragaloside Ⅳ-mediated mTORC1 suppression promotes functional recovery after acute spinal cord injury[J]. J Cell Mol Med, 2020, 24(1): 671-685. doi: 10.1111/jcmm.14776
|
[24] |
OYINBO CA. Secondary injury mechanisms in traumatic spinal cord injury: A nugget of this multiply cascade[J]. Acta Neurobiol Exp, 2011, 71(2): 281-299.
|
[25] |
VON LEDEN RE, YAUGER YJ, KHAYRULLINA G, et al. Central nervous system injury and nicotinamide adenine dinucleotide phosphate oxidase: Oxidative stress and therapeutic targets[J]. J Neurotrauma, 2017, 34(4): 755-764. doi: 10.1089/neu.2016.4486
|
[26] |
ZHANG Y, ZHANG Y, JIN XF, et al. The role of astragaloside Ⅳ against cerebral ischemia/reperfusion injury: Suppression of apoptosis via promotion of P62-LC3-autophagy[J]. Molecules, 2019, 24(9): 1838. doi: 10.3390/molecules24091838
|
[27] |
BEATTIE MS, FAROOQUI AA, BRESNAHAN JC. Review of current evidence for apoptosis after spinal cord injury[J]. J Neurotrauma, 2000, 17(10): 915-925. doi: 10.1089/neu.2000.17.915
|
[28] |
PRADELLI LA, BÉNÉTEAU M, RICCI JE. Mitochondrial control of caspase-dependent and-independent cell death[J]. Cell Mol Life Sci, 2010, 67(10): 1589-1597. doi: 10.1007/s00018-010-0285-y
|
[29] |
KANTARI C, WALCZAK H. Caspase-8 and bid: Caught in the act between death receptors and mitochondria[J]. Biochim Biophys Acta BBA Mol Cell Res, 2011, 1813(4): 558-563. doi: 10.1016/j.bbamcr.2011.01.026
|
[30] |
GALLUZZI L, BLOMGREN K, KROEMER G. Mitochondrial membrane permeabilization in neuronal injury[J]. Nat Rev Neurosci, 2009, 10(7): 481-494. doi: 10.1038/nrn2665
|
[31] |
PLANELLS-FERRER L, URRESTI J, COCCIA E, et al. Fas apoptosis inhibitory molecules: More than death-receptor antagonists in the nervous system[J]. J Neurochem, 2016, 139(1): 11-21. doi: 10.1111/jnc.13729
|
[32] |
SUREDA FX, JUNYENT F, VERDAGUER E, et al. Antiapoptotic drugs: A therapautic strategy for the prevention of neurodegenerative diseases[J]. Curr Pharm Des, 2011, 17(3): 230-245. doi: 10.2174/138161211795049732
|
[33] |
HISATOMI T, ISHIBASHI T, MILLER JW, et al. Pharmacological inhibition of mitochondrial membrane permeabilization for neuroprotection[J]. Exp Neurol, 2009, 218(2): 347-352. doi: 10.1016/j.expneurol.2009.03.007
|